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Human immunodeficiency virus type 1 (HIV-1) tropism can be assessed using phenotypic assays, but this is
quite laborious, expensive, and time-consuming and can be made only in sophisticated laboratories. More
accessible albeit reliable tools for testing of HIV-1 tropism are needed in view of the prompt introduction of
CCR5 antagonists in clinical practice. Bioinformatics tools based on V3 sequences might help to predict HIV-1
tropism; however, most of these methods have been designed by taking only genetic information derived from
HIV-1 subtype B into consideration. The aim of this study was to evaluate the performances of several
genotypic tools to predict HIV-1 tropism in non-B subtypes, as data on this issue are scarce. Plasma samples
were tested using a new phenotypic tropism assay (Phenoscript-tropism; Eurofins), and results were compared
with estimates of coreceptor usage using eight different genotypic predictor softwares (Support Vector Machine
[SVM], C4.5, C4.5 with positions 8 to 12 only, PART, Charge Rule, geno2pheno coreceptor, Position-Specific
Scoring Matrix X4R5 [PSSMX4R5], and PSSMsinsi). A total of 150 samples were tested, with 115 belonging
to patients infected with non-B subtypes and 35 drawn from subtype B-infected patients, which were taken
as controls. When non-B subtypes were tested, the concordances between the results obtained using the
phenotypic assay and distinct genotypic tools were as follows: 78.8% for SVM, 77.5% for C4.5, 82.5% for
C4.5 with positions 8 to 12 only, 82.5% for PART, 82.5% for Charge Rule, 82.5% for PSSMX4R5, 83.8% for
PSSMsinsi, and 71.3% for geno2pheno. When clade B viruses were tested, the best concordances were seen
for PSSMX4R5 (91.4%), PSSMsinsi (88.6%), and geno2pheno (88.6%). The sensitivity for detecting X4
variants was lower for non-B than for B viruses, especially in the case of PSSMsinsi (38.4% versus 100%,
respectively), SVMwetcat (46% versus 100%, respectively), and PART (30% versus 90%, respectively). In
summary, while inferences of HIV-1 coreceptor usage using genotypic tools seem to be reliable for clade
B viruses, their performances are poor for non-B subtypes, in which they particularly fail to detect X4
variants.
To enter human cells, the human immunodeficiency virus
(HIV) type 1 (HIV-1) gp120 envelope glycoprotein interacts
with the cellular CD4 receptor and two main coreceptors,
CCR5 and/or CXCR4. Based on the ability to use CCR5 or
CXCR4, HIV-1 variants are classified as CCR5 tropic (R5),
CXCR4 tropic (X4), or dual-mixed tropic (X4R5) (2). R5
strains are generally responsible for the establishment of early
infection, while the use of the CXCR4 coreceptor is generally
seen in more advanced disease stages. The emergence of X4
variants has generally been associated with a faster CD4 de-
cline and progression to AIDS (15, 28). In addition to the
relationship between coreceptor use and HIV pathogenesis,
the interest in HIV tropism has recently been raised because of
the introduction of CCR5 antagonists in the HIV armamen-
tarium. Two agents, maraviroc and vicriviroc, are the agents
within this family in the latest steps of clinical development (25,
36). Since these drugs show activity against R5 viruses only,
viral tropism testing should be made before their prescription
and eventually during treatment in order to exclude the pres-
ence of X4 viruses.
Although there are several methods to determine HIV-1
tropism, it is unclear at the moment which is the most appro-
priate for routine clinical use (26). Phenotypic assays based on
recombinant viruses seem to be the most accurate methods
(36); however, these methods are quite laborious and expen-
sive and can be used only in sophisticated facilities. Therefore,
more rapid and easier tools are desirable. The HIV-1 envelope
V3 region has been shown to be the major determinant of viral
tropism (5, 30), and accordingly, prediction of coreceptor us-
age based on the interpretation of V3 sequences using bioin-
formatics tools could be a good alternative to infer tropism in
the clinical routine. The first genotypic algorithm designed to
predict HIV-1 tropism took into account only the charge of
amino acids at two key residues located within the V3 loop
(amino acids 11 and 25). Estimates using the “11/25 charge
rule” are relatively satisfactory (3), but other positions within
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the V3 region are currently known to influence viral tropism as
well, causing occasional disagreements (9, 11, 26). For this
reason, most current genotypic bioinformatics tools consider
the entire V3 sequence (27). Moreover, positions outside the
V3 loop may also influence viral tropism (21). More impor-
tantly, most genotypic predictors have been designed based on
the genetic characteristics of HIV-1 clade B (25, 33). Since
non-B subtypes show a wide genetic variability in the V3 region
and since X4 viruses might be more prevalent in some clades
than others (1, 17, 22, 34, 35), there is an urgent need to know
the reliability of genotypic tools for inferring HIV-1 tropism in
non-B subtypes, especially in regions where these HIV-1 vari-
ants are quite prevalent and may soon have access to CCR5
antagonists.
The aim of this study was to evaluate the concordance be-
tween eight distinct bioinformatics tools to estimate HIV-1
coreceptor usage by taking the results of a phenotypic tropism
assay in a relatively large population of patients infected with
non-B subtypes as a reference.
MATERIALS AND METHODS
Study population. Stored plasma specimens from HIV-1-positive patients
known to be infected with non-B subtypes based on reverse transcriptase (RT)
and protease (PR) sequences along the pol gene were identified at three HIV
clinics located in Spain: Hospital Carlos III in Madrid, Hospital Clinico San
Cecilio in Granada, and Hospital de Conxo—CHUS in Santiago de Compostela.
As controls, stored plasma samples matching the same years of collection but
derived from patients infected with clade B viruses were selected in these clinics.
Demographic information as well as viral load, CD4 counts, and antiretroviral
treatment exposure were recorded at the time of analysis. HIV-1 subtyping had
been determined in all samples by phylogenetic analyses of the RT/PR genes
using the PHYLIP software package (version 3.5c; J. Felsenstein, University of
Washington, Seattle, WA). Evolutionary distances were estimated with Dnadist
(Kimura two-parameter method), and phylogenetic relationships were deter-
mined by Neighbor (neighbor-joining method). The branch reproducibility of
trees was evaluated using Seqbot (1,000 replicates) and Consense.
HIV-1 coreceptor usage. Phenotypic coreceptor usage was determined using
the Phenoscript-tropism assay (Eurofins, Kalamazoo, MI). Briefly, amplification
of HIV-1 envelope sequences derived from plasma was initially carried out,
followed by homologous recombination between env amplicons and a deleted
NL43 plasmid of the corresponding region during cotransfection of producer
cells. Recombinant viruses were used to infect indicator cells expressing CCR5 or
CXCR4, besides CD4, and carrying the lacZ gene under control of the viral long
terminal repeat. The specificity of the infection was assessed in each assay by
incubation of indicator cells in the presence and absence of coreceptor inhibitors
and five controls. The sensitivity of detection of minor quasispecies and the
specificity of the Phenoscript-tropism assay were previously reported for clinical
specimens with different viral loads and different HIV-1 non-B variants (29, 33).
Inference of viral tropism using genotypic tools was carried out in parallel in
the same plasma specimens. V3 sequences were amplified by nested PCR using
E80 and E105 as outer primers and ES7 and E125 as inner primers; primers and
PCR conditions were previously described (7, 26). Sequences were edited with
SeqScape v2.5 (Applied Biosystems). Nucleotide mixtures were considered if the
second highest peak in the electropherogram was 25%. Codons containing
mixtures were translated into every possible amino acid, and for each sample, all
possible combinations of V3 amino acid sequences were considered for further
analyses. The V3 sequences generated were then interpreted according to eight
different genotypic predictors available at three Web pages: C4.5, C4.5 with
positions 8 to 12 only, PART, SVM, and Charge Rule (http://genomiac2.ucsd
.edu:8080/wetcat/v3.html) (23); PSSMX4R5 and PSSMsinsi (http://ubik.microbiol
.washington.edu/computing/pssm/) (12, 13); and geno2pheno coreceptor (http:
//coreceptor.bioinf.mpi-sb.mpg.de/cgi-bin/coreceptor.pl) (32). webPSSM may
produce predictions based on subtype B or C (13). In our study, we used
predictions based on subtype B only. For the geno2pheno website, the maximum
sensitivity value for recognizing X4 variants was chosen for predictions. In all
cases, HIV-1 variants were classified as being R5 or X4 tropic, with the latter
including both pure X4 and dual-mixed X4R5 variants.
Statistical analysis. Results were given as percentages or median values with
their interquartile ranges (IQR). Comparisons were performed using nonpara-
metric or chi-square tests. Logistic regression models were used for multivariate
analyses. All reported P values were two sided and were considered to be
significant only when P values were below 0.05. All data were analyzed using
SPSS 13.0 statistical software (SPSS Inc., Chicago, IL).
RESULTS
A total of 150 plasma specimens collected from HIV-1-
infected individuals with enough volume available were iden-
tified at three sites in Spain. Of them, 115 belonged to subjects
infected with non-B subtypes and 35 belonged to patients in-
fected with clade B viruses. The main baseline characteristics
of the study population are summarized in Table 1. Overall,
69.7% were male and 61.4% were antiretrovirally experienced
patients. The median viral load value was 4.4 log HIV RNA
copies/ml, and the median CD4 count was 300 cells/mm3. The
proportion of treatment-experienced patients was significantly
higher in the group infected with clade B than in the group
infected with non-B viruses (82.9% versus 54.3%, respectively;
P  0.003). Moreover, treatment-experienced patients had
significantly lower CD4 counts (271 versus 364 cells/mm3, re-
spectively; P 0.012) and lower plasma HIV RNA levels (4.33
versus 4.54 log copies/ml, respectively; P  0.033) than did
drug-naı¨ve subjects. HIV-1 clade distribution was as follows: 13
A (8.7%), 35 B (23.3%), 13 C (8.7%), 7 D (4.7%), 4 F (2.7%),
24 G (16%), 2 H (1.3%), 2 J (1.3%), 7 CRF01_AE (4.7%), 24
CRF02_AG (16%), 3 CRF11 (2%), 4 CRF12_BF (2.7%), 3
CRF14_BG (2%), 8 URF (5.5%), and 1 undetermined (0.7%).
The phenotypic assay could be successfully performed for
122 (81.3%) specimens, while results using the genotypic tools
could be obtained from 130 (86.7%) specimens. Paired phe-
notypic and genotypic results were available for 115 samples,
80 belonging to non-B subtypes (69.5%) and all 35 clade B




Total Non-B clades Clade B
No. of patients 150 115 35
% of male patients 69.7 66.66 80.64 0.136
Median age (yr) (IQR) 39 (34–45.75) 38 (32–44) 42 (32–48) 0.003
Median plasma HIV RNA copies/ml (IQR) 4.39 (3.64–4.91) 4.42 (3.58–4.91) 4.37 (3.91–4.75) 0.880
Median CD4 count (cells/mm3) (IQR) 300 (144–440) 304 (168–459.5) 262.5 (60–394) 0.096
% CD4 count of 200 cells/mm3 32.4 28.6 44.1 0.093
% of treatment-experienced patients 61.4 54.3 82.9 0.003
% X4/X4R5 dual-tropic viruses 18.9 14.9 28.6 0.123
888 GARRIDO ET AL. J. CLIN. MICROBIOL.
specimens. Failure of amplification was the main reason for
the lack of results for non-B subtypes, most likely due to the
high genetic variability within the envelope region in these
variants.
Some differences in coreceptor usage based on the pheno-
typic information, considering baseline characteristics of the
study population, were found. Overall, 18.9% of samples had
X4 or X4R5 dual-tropic viruses. There were no significant
differences in coreceptor usage when non-B and B samples
were compared (14.9% versus 28.6%, respectively; P  0.123).
However, a higher prevalence of X4 variants was observed in
subjects with CD4 counts below 200 cells/mm3 than in those
with higher CD4 counts (32.4% versus 14.7%, respectively;
P  0.045). X4 variants also tended to be more prevalent in
treatment-experienced than in drug-naı¨ve patients (26.5% ver-
sus 10.6%, respectively; P  0.056). In the multivariate analy-
sis, a 3.6-fold-higher probability of X4 viruses was recognized
for patients with CD4 counts below 200 cells/mm3 regardless of
treatment exposure and HIV-1 clade (P 0.012) [odds ratio
3.6; 95% confidence interval, 1.33 to 9.82]. Consideration of
each of the different HIV-1 subtypes separately did not provide
any remarkable finding, although numbers were too low for
most non-B subtypes tested.
Reliability of genotypic tools to predict coreceptor usage.
The overall concordance between the results obtained using
the distinct genotypic tools taking the phenotypic results as
a reference was always over 76%. Overall, genotypic tools
performed slightly better in testing clade B than non-B
viruses (mean concordance of 85.7% versus 80.2%, respec-
tively). For testing of subtype B samples, the most accurate
bioinformatics tools were PSSMX4R5 (91.4%), PSSMsinsi
(88.6%), and geno2pheno (88.6%), while the best concor-
dance for testing non-B variants was seen with PSSMsinsi
(83.8%), which was closely followed by Charge Rule, PART,
C4.5 with positions 8 to 12 only, and PSSMsinsi, with a
concordance of 82.5% for each one. Overall, no significant
differences in concordance were found by comparing B and
non-B groups, although the most remarkable difference was
found using geno2pheno (88.6% versus 71.3%, respectively;
P  0.056) (Table 2).
SVM, PSSMR5X4, PSSMsinsi, and geno2pheno discordances
generally resulted in an overestimation of X4 viruses, while
other bioinformatics tools tended to underestimate X4 viruses
more frequently. Geno2pheno was the genotypic predictor
more prone to overestimation of X4 tropism (up to 22.5% in
non-B samples), and C4.5 with positions 8 to 12 only was the
genotypic tool that more frequently underestimated X4 (14.8%
of all samples). Of note, a careful examination of subjects with
discordances did not reveal that disagreements between phe-
notypic and genotypic tools could be attributed to differences
in patient characteristics such as viral load, CD4 counts, or
antiretroviral treatment exposure.
The sensitivities and specificities for detecting X4 variants
using distinct genotypic tools are summarized in Table 3. All
genotypic tools showed a higher sensitivity for testing of clade
B than non-B viruses, while the specificity differed according to
the method used. Of note, while geno2pheno showed a good
sensitivity for inferring X4 tropism for clade B viruses, its
TABLE 2. Concordance between results of HIV-1 tropism obtained using genotypic tools and a reference phenotypic assaya
Genotypic tools

























SVMwetcat 80.9 6.1 13 85.7 0 14.3 78.8 8.8 12.5
C4.5 79.1 13 7.8 82.9 14.3 2.9 77.5 12.5 10
C4.5 with positions
8 to 12 only
81.7 14.8 3.5 80 20 0 82.5 12.5 5
PART 82.6 8.7 8.7 82.9 2.9 14.3 82.5 11.3 6.3
Charge Rule 83.5 10.4 6.1 85.7 8.6 5.7 82.5 11.3 6.3
PSSMX4R5 85.2 6.1 8.7 91.4 2.9 5.7 82.5 7.5 10
PSSMsinsi 85.2 7 7.8 88.6 0 11.4 83.2 10 6.3
geno2pheno 76.5 5.2 18.3 88.6 2.9 8.6 71.3 6.3 22.5
a For X4/R5 discordance, Phenoscript-tropism determines X4 dual tropism, while the bioinformatic tool predicts R5 tropism. For R5/X4 discordance, Phenoscript-
tropism determines R5 tropism, while the bioinformatic tool predicts X4 dual tropism.
TABLE 3. Sensitivities and specificities of distinct bioinformatics tools to predict X4 tropism using the results obtained using a phenotypic
assay as a reference
Bioinformatics tool
Sensitivity (%) Specificity (%)
Total B clade Non-B clades Total B clade Non-B clades
SVMwetcat 69 100 46 83 80 85
C4.5 34 50 23 90 96 88
C4.5 with positions 8 to 12 only 26 30 23 95 100 94
PART 56 90 30 89 80 92
Charge Rule 47 70 30 92 92 92
PSSMX4R5 69 90 53 89 92 88
PSSMsinsi 62.5 100 38.4 91.2 84 92.5
geno2pheno 74 90 61 77 88 73
VOL. 46, 2008 GENOTYPIC TOOLS TO PREDICT TROPISM IN HIV-1 SUBTYPES 889
specificity was the worst for non-B subtypes. An overestimation
of X4 viruses, mainly for non-B subtypes, was the main reason
for this behavior.
DISCUSSION
The imminent approval of CCR5 antagonists for the treat-
ment of HIV-1 infection has significantly raised interest in viral
tropism. In general, coreceptor usage must be known before
these drugs are prescribed. While phenotypic tests are consid-
ered to be the “gold standard,” they are laborious and costly
and require sophisticated facilities and experienced personnel.
Genotypic predictors of HIV-1 tropism have been developed
to circumvent these disadvantages; however, the high genetic
variability of HIV-1 may represent a serious obstacle to ensure
their reliability. In addition to these diagnostic obstacles, it is
important to better understand HIV pathogenesis and explain
why some HIV-1 clades seem to be more frequently X4 tropic
than others, as recently claimed for subtypes A, D, and
CRF14_BG (1, 10, 14, 17, 22), since patients infected with
these variants might progress faster to AIDS and will benefit
less from CCR5 antagonists.
In this study, we evaluated the prevalence of X4 or X4R5
dual-tropic viruses in a relatively large population of non-B
HIV-1 clinical specimens. Up to 19% of these individuals car-
ried X4/X4R5 dual-tropic viruses, with no significant differ-
ences with a control group of patients infected with clade B
viruses. In other studies that included a larger number of
samples from clades C and D, it was noted that clade C might
less frequently harbor X4 viruses, even in late disease stages (8,
16, 20, 24, 31), while conversely, clade D could be X4 tropic
more frequently (10, 14). The small number of samples with
these variants in our study precluded the examination of this
aspect more appropriately.
A significantly higher prevalence of X4 and X4/R5 dual-
tropic viruses was found in patients with lower CD4 counts,
which is in agreement with previously reported observations
and with the notion that these HIV-1 variants tend to be
selected as immunodeficiency progresses (3, 14, 15, 31). A
higher prevalence of X4/X4R5 viruses also tended to be asso-
ciated with prior exposure to antiretroviral therapy, which is
also in agreement with previously reported observational data
from cross-sectional surveys (11, 19).
The accuracy of genotypic tools to assess viral tropism based
on V3 sequences was previously examined mostly in samples
collected from patients infected with clade B viruses, using
phenotypic tests as a comparison (4, 18, 26). To our knowl-
edge, this is the first study to assess the performances of var-
ious genotypic bioinformatics tools to predict HIV-1 tropism in
non-B subtypes using the results obtained with a phenotypic
test as a reference. In the present study, we have sequenced the
V3 region for the bulk viral population. Moreover, we also
considered minority species by assessing nucleotide mixtures in
the electropherogram. Molecular cloning of each sample
seems to be the best method to detect mixed populations, but
it is much more complicated, and it seems to produce very
similar results (6).
By comparing the results obtained using genotypic tools and
the phenotypic assay in the whole population, there was a
relatively good concordance (mean of 81.3%, ranging from
76% using geno2pheno to 85.5% using the charge rule). Most
genotypic algorithms, however, performed better for testing
clade B than non-B viruses. The most pronounced differences
were found using PSSM and geno2pheno, most likely because
they are designed exclusively based on clade B strains, while
the wetcat system has been built with both B and non-B se-
quences.
Considering that the main application for the V3 genotypic
algorithms in clinical settings will be for excluding the presence
of X4 or X4R5 dual-tropic variants in patients in whom CCR5
antagonists might be considered as potential therapy, it is man-
datory to know the sensitivity and specificity of each of these
genotypic tools precisely. Our results showed that the specific-
ity was above 80% when either B or non-B variants were tested
by all the different genotypic tools except geno2pheno (77%).
Moreover, geno2pheno showed the highest differences when B
and non-B samples were compared, obtaining a specificity of
73% for non-B and 88% for B specimens. However, the sen-
sitivity for the detection of X4 variants differed substantially
when distinct genotypic tools were used according to HIV-1
subtype. The sensitivities of SVM and PSSMsinsi were 100% for
clade B viruses, while they were only 46% and 38.4%, respec-
tively, for non-B clades. The highest sensitivity for recognizing
X4 viruses when testing non-B subtypes was seen for
geno2pheno, although it was only 61%, which may be consid-
ered to be unacceptable for clinical use to replace phenotypic
tests.
This study has several limitations. First, although the entire
set of non-B subtypes examined included a relatively large
number of clinical samples, some HIV-1 clades were not or
only scarcely represented. Second, only one phenotypic assay
was used as a reference, and disagreement between distinct
phenotypic tests for determining HIV-1 coreceptor usage in
pairwise plasma samples has recently been highlighted, being
of up to 15% in one recent study (33). Third, phenotypic and
genotypic results could not be obtained from 14 to 19% of
specimens belonging to patients infected with non-B subtypes,
and therefore, the concordance between phenotypic and ge-
notypic tropism results could have been slightly overestimated.
In conclusion, estimations of HIV-1 tropism using bioinfor-
matics tools based on V3 sequences are better for testing clade
B than non-B viruses. Moreover, the sensitivity for detecting
X4 variants differed substantially according to HIV-1 subtype.
In light of their low sensitivity, it should be advisable not to rely
on genotypic tools to exclude X4 variants in patients infected
with non-B subtypes.
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